Rilvegostomig

Summary

Rilvegostomig (CHEMBL5314706) is a phase-3 clinical-stage antibody; indicated across 7 conditions including non-small cell lung carcinoma and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 7 conditions
• Clinical trials: 31

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314706
Name	Rilvegostomig
Type	Antibody
Max phase	3

Also known as: Azd 2936, AZD-2936, Azd2936, AZD2936, Rilvegostomig, RILVEGOSTOMIG

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
neoplasm	2	MONDO:0005070	EFO:0000616
head and neck squamous cell carcinoma	2	MONDO:0010150	EFO:0000181
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
gastric neoplasm	2	MONDO:0021085	EFO:0003897

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 31.

Phase distribution

Phase	Trials
PHASE3	12
PHASE2	11
PHASE1/PHASE2	3
PHASE1	3
EARLY_PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06109779	PHASE3	ACTIVE_NOT_RECRUITING	Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT06357533	PHASE3	RECRUITING	Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06467357	PHASE3	RECRUITING	Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06564844	PHASE3	ACTIVE_NOT_RECRUITING	A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
NCT06627647	PHASE3	RECRUITING	A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
NCT06692738	PHASE3	RECRUITING	A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06764875	PHASE3	RECRUITING	A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06868277	PHASE3	RECRUITING	A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06921785	PHASE3	RECRUITING	Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06989112	PHASE3	RECRUITING	DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT07221253	PHASE3	RECRUITING	A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07431281	PHASE3	RECRUITING	Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT01042379	PHASE2	RECRUITING	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT04379596	PHASE2	RECRUITING	Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
NCT04995523	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
NCT05061550	PHASE2	RECRUITING	Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
NCT05414032	PHASE2	RECRUITING	Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC
NCT05489211	PHASE2	RECRUITING	Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05702229	PHASE2	RECRUITING	Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05775159	PHASE2	RECRUITING	Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
NCT06630130	PHASE2	RECRUITING	Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer
NCT06996782	PHASE1/PHASE2	RECRUITING	A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT07069712	PHASE2	RECRUITING	A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
NCT07098338	PHASE2	RECRUITING	A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
NCT07115043	PHASE1/PHASE2	RECRUITING	A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT07128290	PHASE2	NOT_YET_RECRUITING	PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma
NCT03819465	PHASE1	ACTIVE_NOT_RECRUITING	A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
NCT04612751	PHASE1	ACTIVE_NOT_RECRUITING	Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04686305	PHASE1	RECRUITING	Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
NCT04541108	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
NCT06366451	EARLY_PHASE1	RECRUITING	PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).